Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell death

BACKGROUND: Dexrazoxane (DEX, ICRF-187) is the only clinically approved cardioprotectant against anthracycline cardiotoxicity. It has been traditionally postulated to undergo hydrolysis to iron-chelating agent ADR-925 and to prevent anthracycline-induced oxidative stress, progressive cardiomyocyte d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Popelová, O, Štěrba, M, Hašková, P, Šimůnek, T, Hroch, M, Gunčová, I, Nachtigal, P, Adamcová, M, Geršl, V, Mazurová, Y
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2009
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2736842/
https://ncbi.nlm.nih.gov/pubmed/19623174
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6605192
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados